TITLE

Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer

AUTHOR(S)

Khan, Z.M.; Rascati, K.L.; Koeller, J.M.

PUB. DATE

July 1999

SOURCE

PharmacoEconomics;1999, Vol. 16 Issue 1, p43

SOURCE TYPE

Academic Journal

DOC. TYPE

journal article

ABSTRACT

Objective: To conduct an economic analysis on the use of carboplatin versus cisplatin over multiple courses in patients with lung [nonsmall cell lung cancer (NSCLC) and small cell lung cancer (SCLC)] or ovarian cancer.Design: This 1-year study was a prospective, multicentre, cost-minimisation evaluation. Direct medical resource utilisation and costs associated with carboplatin and cisplatin administration over 3 to 6 courses of treatment were measured and compared. The perspective of this evaluation was that of the payer.Setting: A convenience sample of 16 sites representing a mix of cancer centres, outpatient clinics, medical centres and managed-care sites in a general practice oncology setting participated.Patients and Interventions: Patients were included in this study if they were newly diagnosed with NSCLC, SCLC or ovarian cancer, had not received prior chemotherapy, received either carboplatin or cisplatin as their treatment (additional chemotherapy agents were allowed), and received at least 3 courses of carboplatin or cisplatin therapy up to a maximum of 6 courses. Patients receiving more than 6 courses of therapy were included in this study, but data collection on those patients stopped after the sixth course. Individuals involved with data collection at all sites were trained via on-site and/or teleconference training. Site visits were made to assure reliability of at least 0.80. Data were collected and compiled via a fax transmission process that scans directly through optical mark and character recognition into a computer database. Outcome measures included costs of: medications, emergency room visits, physician/clinic/laboratory visits, home healthcare visits, transfusions, special procedures, consultations, hospitalisations and other/miscellaneous costs.Main Outcome Measures and Results: Of 220 patients, 164 met the study criteria (response rate = 74.2%) with 95 patients in the carboplatin group (NSCLC = 45, SCLC = 18, ovarian = 32) and 69 in the cisplatin group (NSCLC = 36, SCLC = 21, ovarian = 12). The average number of courses were: NSCLC = 4.3 and 4.2, SCLC = 4.3 and 4.8, and ovarian = 4.7 and 5.1, respectively, for carboplatin and cisplatin. The total costs (treatment and toxicity) associated with the use of carboplatin were higher in NSCLC, similar in SCLC but lower in ovarian cancer.Conclusions: These results indicate that overall treatment costs may vary depending on cancer type, even when the same drugs are used. The total costs (treatment plus toxicity costs) associated with the use of carboplatin were higher than those of cisplatin in patients with NSCLC, similar in SCLC, but lower in ovarian cancer.

ACCESSION #

9523777

 

Related Articles

• The economic consequences of breast cancer adjuvant hormonal treatments. Pezzin, Liliana E.; O'Niel, Mallory B.; Nattinger, Ann B. // JGIM: Journal of General Internal Medicine;Nov2009 Supplement 2, Vol. 24, p446 

  Rationale: Adjuvant hormone therapy (HT) based on tamoxifen (TX) or aromatase inhibitors (AIs) has become the standard of care for treating hormone receptor -positive (HR+) breast cancer (BC) over the past 20 years. Based on clinical trial results, AI use is recommended by the...

• Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. Lee, Su Jin; Kim, Sungmin; Kim, Moonjin; Lee, Jeeyun; Park, Yeon Hee; Im, Young-Hyuck; Park, Se Hoon // BMC Cancer;2015, Vol. 15 Issue 1, p693 

  Background: The aim of this study was to assess the efficacy and safety of a combination regimen of capecitabine plus cisplatin (CC) or capecitabine plus paclitaxel (CP) as a first-line treatment in patients with metastatic esophageal squamous cell carcinoma.Methods:...

• Effect of Using the HEART Score in Patients With Chest Pain in the Emergency Department: A Stepped-Wedge, Cluster Randomized Trial. Poldervaart, Judith M.; Reitsma, Johannes B.; Backus, Barbra E.; Koffijberg, Hendrik; Veldkamp, Rolf F.; ten Haaf, Monique E.; Appelman, Yolande; Mannaerts, Herman F. J.; van Dantzig, Jan-Melle; van den Heuvel, Madelon; el Farissi, Mohamed; Rensing, Bernard J. W. M.; Ernst, Nicolette M. S. K. J.; Dekker, Ineke M. C.; den Hartog, Frank R.; Oosterhof, Thomas; Lagerweij, Ghizelda R.; Buijs, Eugene M.; van Hessen, Maarten W. J.; Landman, Marcel A. J. // Annals of Internal Medicine;5/16/2017, Vol. 166 Issue 10, Following p689 

  Background: The HEART (History, Electrocardiogram, Age, Risk factors, and initial Troponin) score is an easy-to-apply instrument to stratify patients with chest pain according to their short-term risk for major adverse cardiac events (MACEs), but its effect on daily practice is...

• TEL-AML1 fusion transcript designates a favorable outcome with an intensified protocol in childhood acute lymphoblastic leukemia. Avigad, S; Kuperstein, G; Zilberstein, J; Liberzon, E; Stark, B; Gelernter, I; Kodman, Y; Luria, D; Ash, S; Stein, J; Goshen, Y; Yaniv, I; Cohen, I J; Zaizov, R // Leukemia (08876924);Mar99, Vol. 13 Issue 3, p481 

  Analyzes B-lineage childhood acute lymphoblastic leukemia patients for the acute myelocytic leukemia fusion transcript at diagnosis and correlates the findings with duration of remission. Details of patients diagnosed; Event free survival rates of patients; Treatment protocols used in the study.

• Randomised Comparison of a Novel Buprenorphine Oral Lyophilisate versus Existing Buprenorphine Sublingual Tablets in Opioid-Dependent Patients: A First-in-Patient Phase II Randomised Open Label Safety Study. Strang, John; Reed, Kylie; Bogdanowicz, Karolina; Bell, James; van der Waal, Rob; Keen, Jenny; Beavan, Pete; Baillie, Shelagh; Knight, alastair // European Addiction Research;May2017, Vol. 23 Issue 2, p61 

  Aims: To test the safety of new buprenorphine oral lyophilisate wafer ("bup-lyo") versus standard sub-lingual buprenorphine ("bup-SL").Design: Randomised (2:1) open-label study; opioid-dependent subjects; subsequent partial cross-over.Settings: Specialised...

• Efficacy and safety of recombinant human lymphotoxin-α derivative with cisplatin and fluorouracil in patients with metastatic esophageal squamous cell carcinoma: A randomized, multicenter, open-label, controlled, phase 2b trial. Wang, Feng‐hua; Wang, Yun; Sun, Guo‐ping; Chen, Jian‐hua; Lin, Ying‐cheng; Liu, Wei; Zheng, Rong‐sheng; Chen, Jia; Zhang, He‐long; Lan, Hai‐tao; Qi, Jun; Liu, Yang‐qing; Deng, Yan‐ming; Zhao, Heng; Xiong, Jian‐ping; Xu, Qing; Jiang, Wen‐qi; Li, Yu‐hong // Cancer (0008543X);Oct2017, Vol. 123 Issue 20, p3986 

  Background: Recombinant human lymphotoxin-α derivative (rhLTα-Da) is a lymphotoxin-α derivative that is missing 27 N-terminal amino acid residues. Previous studies indicated a benefit from the addition of rhLTα-Da to cisplatin-based treatment in patients with metastatic...

• Cisplatin/carboplatin.  // Reactions Weekly;7/22/2006, Issue 1111, p10 

  The article presents a case study of a 47-year-old woman who was diagnosed with cancer metastases while being treated with cisplatin and carboplatin for ovarian cancer.

• Haloperidol decanoate v. fluphenazine decanoate as maintenance therapy in chronic schizophrenic in-patients. McKane, J. P.; Robinson, A. D. T.; Wiles, O. H.; McCreadie, R. G.; Stirling, G. S.; Robinson, A D; Wiles, D H // British Journal of Psychiatry;Sep87, Vol. 151, p333 

  In a double-blind study of 38 chronic schizophrenic in-patients, haloperidol decanoate was compared with fluphenazine decanoate as maintenance therapy over 60 weeks. Both drugs were given by injection at 4-week intervals. Haloperidol and fluphenazine were assumed to be equipotent; the mean...

• Acute blocking of naloxone-precipitated opiate withdrawal symptoms by methohexitone. Loimer, N.; Schmid, R.; Lenz, K.; Presslich, O.; Grünberger, J.; Grünberger, J // British Journal of Psychiatry;Nov90, Vol. 157, p748 

  In a double-blind placebo-controlled trial of 18 patients, methohexitone blocked objective signs of opiate withdrawal caused by a bolus injection of naloxone. Furthermore, in continuing the naloxone therapy for 48 hours, no withdrawal signs appeared. Levels of withdrawal distress returned to...

Read the Article